These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33864515)

  • 1. Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study.
    Donzuso G; Sciacca G; Rascunà C; Cicero CE; Mostile G; Nicoletti A; Zappia M
    J Neurol; 2021 Nov; 268(11):4258-4264. PubMed ID: 33864515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-duration response to L-dopa in the treatment of early PD.
    Zappia M; Oliveri RL; Bosco D; Nicoletti G; Branca D; Caracciolo M; Napoli ID; Gambardella A; Quattrone A
    Neurology; 2000 May; 54(10):1910-5. PubMed ID: 10822428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Sciacca G; Mostile G; Disilvestro I; Donzuso G; Nicoletti A; Zappia M
    Mov Disord; 2023 Apr; 38(4):626-635. PubMed ID: 36840442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Brissenden JA; Scerbak T; Albin RL; Lee TG
    Mov Disord; 2024 Jan; 39(1):76-84. PubMed ID: 38062630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional gray matter changes and age predict individual treatment response in Parkinson's disease.
    Ballarini T; Mueller K; Albrecht F; Růžička F; Bezdicek O; Růžička E; Roth J; Vymazal J; Jech R; Schroeter ML
    Neuroimage Clin; 2019; 21():101636. PubMed ID: 30558868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
    Ondo W
    Expert Opin Pharmacother; 2014 Oct; 15(14):2081-5. PubMed ID: 25146967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-duration action of levodopa may be due to a postsynaptic effect.
    Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.
    Gul A; Yousaf J
    Singapore Med J; 2019 Aug; 60(8):414-417. PubMed ID: 30246215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease.
    Arena JE; Cerquetti D; Rossi M; Chaves H; Rollan C; Dossi DE; Merello M
    Parkinsonism Relat Disord; 2016 Mar; 24():126-8. PubMed ID: 26823237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
    Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
    Wider C; Russmann H; Villemure JG; Robert B; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
    Arch Neurol; 2006 Jul; 63(7):951-5. PubMed ID: 16831963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The increased gray matter volumes of precentral gyri in Parkinson's disease patients with diphasic dyskinesia.
    Zhi Y; Wang M; Yuan YS; Shen YT; Ma KW; Gan CT; Si QQ; Wang LN; Cao SW; Zhang KZ
    Aging (Albany NY); 2019 Nov; 11(21):9661-9671. PubMed ID: 31699957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The subacute levodopa test for evaluating long-duration response in Parkinson's disease.
    Quattrone A; Zappia M; Aguglia U; Branca D; Colao R; Montesanti R; Nicoletti G; Palmieri A; Parlato G; Rizzo M
    Ann Neurol; 1995 Sep; 38(3):389-95. PubMed ID: 7668824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological Correlates of Neuroanatomical Changes in a Rat Model of Levodopa-Induced Dyskinesia Based on Voxel-Based Morphometry.
    Zhang X; Chen W; Wu Y; Zeng W; Yuan Y; Cheng C; Yang X; Wang J; Yang X; Xu Y; Lei H; Cao X; Xu Y
    Front Aging Neurosci; 2021; 13():759934. PubMed ID: 34776935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: a VBM study; the Parkinson's Disease Cognitive Impairment Study (PaCoS).
    Donzuso G; Monastero R; Cicero CE; Luca A; Mostile G; Giuliano L; Baschi R; Caccamo M; Gagliardo C; Palmucci S; Zappia M; Nicoletti A
    Neurol Sci; 2021 Sep; 42(9):3723-3731. PubMed ID: 33447925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.